Physiogenex is a renowned CRO biotechnology leader specializing in metabolic and cardiovascular diseases. In this focused niche market we offer dedicated in-house and R&D customized solutions designed to help our partners optimize their drug discovery and preclinical development on a fee-for-service basis.
Physiogenex pioneers the development of radiotracer-based kinetic methods and predictive animal nutritional models, thus providing our partners with the pertinent and reliable discovery and preclinical data they need for successful strategic decision-making. Physiogenex has rapidly achieved global player status by virtue of its unique expertise covering complex metabolic disorders associated with diabetes, obesity, lipid disorders, hypertension and cardiovascular diseases.
Physiogenex is an entrepreneurial, science-driven company dedicated to helping pharmaceutical, biotechnology and agro-food companies reduce their drug development costs by integrating clinical issues as soon as the discovery and preclinical drug development process.
Successfully anticipating clinical drug development in metabolic and cardiovascular diseases
